Neutralization of Omicron BA.1, BA.5.1.6, BQ.1.3 and XBB1.1 induced by heterologous vaccination Ad5-nCoV and mRNA-1273

Neutralization of Omicron BA.1, BA.5.1.6, BQ.1.3 and XBB1.1 induced by heterologous vaccination Ad5-nCoV and mRNA-1273

Bibliographic Details
Main Authors:	Jesús Hernández, Freddy Dehesa-Canseco, Alma B. Vázquez-López, Mónica Reséndiz-Sandoval, Graciela Caire-Juvera, Mario Solís-Hernández, Olivia Valenzuela, Bruno Gómez-Gil, Verónica Mata-Haro
Format:	Article
Language:	English
Published:	Nature Publishing Group 2023-04-01
Series:	Signal Transduction and Targeted Therapy
Online Access:	https://doi.org/10.1038/s41392-023-01447-y

Similar Items

Characterization of Omicron BA.4.6, XBB, and BQ.1.1 subvariants in hamsters
by: Peter J. Halfmann, et al.
Published: (2024-03-01)

In silico prediction of siRNA to silence the SARS-CoV-2 omicron variant targeting BA.4, BA.5, BQ.1, BQ1.1. and XBB: an alternative to traditional therapeutics
by: Rahatul Islam, et al.
Published: (2023-08-01)

Antigenic characterization of SARS-CoV-2 Omicron subvariants XBB.1.5, BQ.1, BQ.1.1, BF.7 and BA.2.75.2
by: Airu Zhu, et al.
Published: (2023-03-01)

Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron
by: Masayuki Amano, et al.
Published: (2023-10-01)

Heterologous inactivated virus/mRNA vaccination response to BF.7, BQ.1.1, and XBB.1
by: Fanglei Zuo, et al.
Published: (2023-04-01)

BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer
by: Rajesh M. Valanparambil, et al.
Published: (2023-11-01)

Effectiveness and durability of mRNA-1273 BA.4/BA.5 bivalent vaccine (mRNA-1273.222) against SARS-CoV-2 BA.4/BA.5 and XBB sublineages
by: Bradley K. Ackerson, et al.
Published: (2024-12-01)

COVID-19 Bivalent Booster in Pregnancy: Maternal and Neonatal Antibody Response to Omicron BA.5, BQ.1, BF.7 and XBB.1.5 SARS-CoV-2
by: Wei-Chun Chen, et al.
Published: (2023-08-01)

In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1
by: Andrei A. Pochtovyi, et al.
Published: (2023-09-01)

Comparative pathogenicity of BA.2.12, BA.5.2 and XBB.1 with the Delta variant in Syrian hamsters
by: Sreelekshmy Mohandas, et al.
Published: (2023-06-01)

Renewed global threat by the novel SARS-CoV-2 variants ‘XBB, BF.7, BQ.1, BA.2.75, BA.4.6’: A discussion
by: Ranjan K. Mohapatra, et al.
Published: (2022-12-01)

Therapeutic potential of convalescent plasma and hyperimmune immunoglobulins against SARS-CoV-2 BQ.1, BQ.1.1, and XBB variants
by: Lorenza Bellusci, et al.
Published: (2023-04-01)

Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
by: Hung Fu Tseng, et al.
Published: (2023-01-01)

Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies
by: Delphine Planas, et al.
Published: (2023-02-01)

The rapid rise of SARS‐CoV‐2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants
by: Danyi Ao, et al.
Published: (2023-04-01)

Omicron BQ.1.1 and XBB.1 unprecedentedly escape broadly neutralizing antibodies elicited by prototype vaccination
by: Bin Ju, et al.
Published: (2023-06-01)

SARS-CoV-2 Variants BQ.1 and XBB.1.5 in Wastewater of Aircraft Flying from China to Denmark, 2023
by: Amanda Gammelby Qvesel, et al.
Published: (2023-12-01)

Neutralization of Omicron XBB.1 by booster vaccination with BA.4/5 monovalent mRNA vaccine
by: Hui Zhao, et al.
Published: (2024-01-01)

Neutralization of SARS-CoV-2 Omicron BQ.1, BQ.1.1 and XBB.1 variants following SARS-CoV-2 infection or vaccination in children
by: Lorenza Bellusci, et al.
Published: (2023-12-01)

Deep mutational scans of XBB.1.5 and BQ.1.1 reveal ongoing epistatic drift during SARS-CoV-2 evolution.
by: Ashley L Taylor, et al.
Published: (2023-12-01)

Assessment of neutralization susceptibility of Omicron subvariants XBB.1.5 and BQ.1.1 against broad-spectrum neutralizing antibodies through epitopes mapping
by: Masaud Shah, et al.
Published: (2023-09-01)

Neutralization of SARS-CoV-2 BQ.1.1, CH.1.1, and XBB.1.5 by breakthrough infection sera from previous and recent waves in China
by: Xun Wang, et al.
Published: (2023-06-01)

Immune Evasion of SARS-CoV-2 Omicron Subvariants XBB.1.5, XBB.1.16 and EG.5.1 in a Cohort of Older Adults after ChAdOx1-S Vaccination and BA.4/5 Bivalent Booster
by: Rafael Rahal Guaragna Machado, et al.
Published: (2024-01-01)

Dynamic immune landscape in vaccinated-BA.5-XBB.1.9.1 reinfections revealed a 5-month protection-duration against XBB infection and a shift in immune imprintingResearch in context
by: Tingting Cui, et al.
Published: (2024-01-01)

Second booster dose improves antibody neutralization against BA.1, BA.5 and BQ.1.1 in individuals previously immunized with CoronaVac plus BNT162B2 booster protocol
by: Guilherme R. F. Campos, et al.
Published: (2024-04-01)

Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 six months after the BNT162b2 bivalent booster
by: Julien Favresse, et al.
Published: (2024-06-01)

Sera from breakthrough infections with SARS-CoV-2 BA.5 or BF.7 showed lower neutralization activity against XBB.1.5 and CH.1.1
by: Shuo Liu, et al.
Published: (2023-12-01)

Neutralization against XBB.1 and XBB.1.5 after omicron subvariants breakthrough infection or reinfection
by: Jin-Jin Chen, et al.
Published: (2023-04-01)

A COVID-19 DNA Vaccine Candidate Elicits Broadly Neutralizing Antibodies against Multiple SARS-CoV-2 Variants including the Currently Circulating Omicron BA.5, BF.7, BQ.1 and XBB
by: Yuan Ding, et al.
Published: (2023-03-01)

Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination
by: Wang-Huei Sheng, et al.
Published: (2022-04-01)

Neutralizing Activity against BQ.1.1, BN.1, and XBB.1 in Bivalent COVID-19 Vaccine Recipients: Comparison by the Types of Prior Infection and Vaccine Formulations
by: Hak-Jun Hyun, et al.
Published: (2023-08-01)

Clinical phenotypes and outcomes associated with SARS-CoV-2 Omicron variants BA.2, BA.5 and BQ.1.1 in critically ill patients with COVID-19: a prospective, multicenter cohort study
by: Nicolas de Prost, et al.
Published: (2023-08-01)

Less neutralization evasion of SARS-CoV-2 BA.2.86 than XBB sublineages and CH.1.1
by: Yanping Hu, et al.
Published: (2023-12-01)

Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection
by: Khadija Khan, et al.
Published: (2022-08-01)

Omicron Waves in Argentina: Dynamics of SARS-CoV-2 Lineages BA.1, BA.2 and the Emerging BA.2.12.1 and BA.4/BA.5
by: Carolina Torres, et al.
Published: (2023-01-01)

SARS-CoV-2 omicron BA.5 and XBB variants have increased neurotropic potential over BA.1 in K18-hACE2 mice and human brain organoids
by: Romal Stewart, et al.
Published: (2023-11-01)

Low levels of neutralizing antibodies against XBB Omicron subvariants after BA.5 infection
by: Jingyun Yang, et al.
Published: (2023-06-01)

XBB.1.5 emerges in the Americas: what it means to the region
by: Peter Hotez
Published: (2023-02-01)

Broad protective RBD heterotrimer vaccines neutralize SARS-CoV-2 including Omicron sub-variants XBB/BQ.1.1/BF.7.
by: Yanfang Zhang, et al.
Published: (2023-09-01)

Author Correction: Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection
by: Khadija Khan, et al.
Published: (2022-10-01)